64 completed, 14 terminated, 12 recruiting, 6 unknown. 105 Phase 2, 10 Phase 3, 4 Phase 1.
Follow Proteinuria: new trials by email Literature Review of Proteinuria trials Research Report on Proteinuria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy Mycophenolate Mofetil (MMF), Prednisolon - IgA Nephropathy | Phase 2 | Not yet recruiting | Shaheed Suhrawardy Medical College and Hospital | 104 | 2026-09-01 | 2026-08-25 |
| Mesenchymal Stem Cell Exosomes Alone or Combined With HUVEC Exosomes in Non-Dialysis Chronic Kidney Disease Human Wharton's jelly mesenchymal stem cell (HWJ-MSC) exosomes, Human umbilical vein endothelial cell (HUVEC) exosomes, Placebo (0.9% sodium chloride) - Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4 | Phase 1 / Phase 2 | Completed | Nurhasan Agung Prabowo | 34 | 2026-07-01 | 2026-11-06 |
| A Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101 - IgA Nephropathy | Phase 2 | Recruiting | Jade Biosciences, Inc. | 30 | 2026-05-19 | 2026-10-30 |
| Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin Empagliflozin (oral) - Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria | Phase 2 | Recruiting | University of Illinois at Chicago | 20 | 2026-04-08 | 2026-05-19 |
| Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i ARBs alone, ARBs in combination of SGLT2i - Proteinuria, Diabetes (DM) | Phase 2 / Phase 3 | Active not recruiting | Dr Mudassar Saeed Pansota | 60 | 2026-04-06 | 2026-05-14 |
| A Study to Assess the Effects of Zigakibart on IgA Nephropathy. zigakibart - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 32 | 2026-03-26 | 2026-10-21 |
| Huaier Granule and Proteinuria Huaier Granule, Antitumor therapy, Proteinuria Management - Proteinuria, Breast Cancer Patients | Phase 2 | Not yet recruiting | Fudan University | 120 | 2026-01-15 | 2026-01-21 |
| A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B) - Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Akebia Therapeutics | 60 | 2025-12-03 | 2026-11-09 |
| SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome Dapagliflozin, Empagliflozin, Standard Therapy - Nephrotic Syndrome | Phase 2 / Phase 3 | Recruiting | Mansoura University | 75 | 2025-11-15 | 2026-06-09 |
| A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen - Diabetic Kidney Disease (DKD), Type 2 Diabetes | Phase 2 | Active not recruiting | Beijing University of Chinese Medicine | 15 | 2025-10-20 | 2026-11-02 |
| Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study Hydroxychloroquine Oral Tablet, Placebo oral tablet - IgA Nephropathy | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 334 | 2025-06-26 | 2026-10-09 |
| Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis Finerenone, Placebo - Glomerulonephritis | Phase 2 | Completed | Alexandria University | 100 | 2025-04-01 | 2026-05-28 |
| Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia Sotagliflozin, Placebo - Nephropathy, Diabetic Nephropathies | Phase 2 | Not yet recruiting | Steno Diabetes Center Copenhagen | 69 | 2025-02-01 | 2025-01-27 |
| The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease dapagliflozin, Other anti-diabetic drug or no anti-diabetic drug, empagliflozin - Acute Kidney Injury | Phase 2 | Recruiting | National Taiwan University Hospital | 264 | 2024-11-21 | 2026-01-02 |
| Effect Camostat for Kidney Protection in Chronic Kidney Disease Camostat Mesylate - Chronic Kidney Disease(CKD) | Phase 2 | Recruiting | Odense University Hospital | 40 | 2024-11-21 | 2025-01-27 |
| Safety and Efficacy of the Combination Therapy of Fucoidan / Fucoxanthin / L-carnitine in Patients With Diabetic Nephropathy. Oligo-fucoidan, Fucoxanthin, L-carnitine Formula, Zinc yeast (FFL) - Diabetic Kidney Disease (DKD) | Phase 2 | Completed | Taipei Medical University WanFang Hospital | 63 | 2024-11-06 | 2026-09-04 |
| Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease amiloride, Placebo - Chronic Kidney Disease(CKD), Proteinuria | Phase 2 | Recruiting | Odense University Hospital | 40 | 2024-10-10 | 2025-04-11 |
| The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study Finerenone Oral Tablet, Placebo - Kidney Transplant; Complications | Phase 2 | Recruiting | University of North Carolina, Chapel Hill | 100 | 2024-04-23 | 2026-04-14 |
| Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD - Chronic Kidney Disease | Phase 2 | Completed | Mineralys Therapeutics Inc. | 60 | 2023-12-14 | 2026-06-03 |
Showing 20 of 105. Sign in to see all of them.
Albuminuria (31) · Diabetic Nephropathies (25) · Renal Insufficiency, Chronic (24) · Kidney Diseases (14) · Diabetes Mellitus, Type 2 (13) · Nephrotic Syndrome (11) · Glomerulosclerosis, Focal Segmental (10) · Glomerulonephritis (8) · Glomerulonephritis, IGA (8) · Hypertension (8) · Diabetes Mellitus (7) · Hemoglobinuria (6) · Hemoglobinuria, Paroxysmal (6) · Anemia, Sickle Cell (5)
Female Urogenital Diseases (105) · Female Urogenital Diseases and Pregnancy Complications (105) · Male Urogenital Diseases (105) · Pathological Conditions, Signs and Symptoms (105) · Signs and Symptoms (105) · Urological Manifestations (105) · Urogenital Diseases (104) · Urologic Diseases (104) · Urination Disorders (103) · Kidney Diseases (62) · Endocrine System Diseases (36) · Pathologic Processes (30) · Diabetes Mellitus (29) · Disease Attributes (26)
dapagliflozin (8) · Atorvastatin (4) · Cyclosporine (4) · Atrasentan (3) · Rituximab (3) · Standard of Care (3) · empagliflozin (3) · Acetylcysteine (2) · Amiloride (2) · Cyclophosphamide (2) · Glucocorticoids (2) · Irbesartan (2) · Levamisole (2) · Mycophenolic Acid (2) · Nifedipine (2)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7) · AstraZeneca (5) · Mario Negri Institute for Pharmacological Research (4) · AbbVie (prior sponsor, Abbott) (3) · Novartis Pharmaceuticals (3) · Alexion Pharmaceuticals, Inc. (2) · Fudan University (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Odense University Hospital (2) · Pfizer (2) · Shiraz University of Medical Sciences (2) · University Medical Center Groningen (2) · University of Alabama at Birmingham (2) · University of North Carolina, Chapel Hill (2) · Akebia Therapeutics (1)
United States (55) · Italy (15) · Canada (12) · United Kingdom (11) · Australia (10) · Germany (10) · Spain (9) · Brazil (8) · China (8) · Denmark (8) · France (8) · Netherlands (8) · Poland (8) · South Korea (8) · Taiwan (8)
Jeffrey B Kopp, M.D. (2) · Alireza Amir Maafi, MD Student (1) · Amin Banihashemi (1) · Amy Mottl, MD, MPH (1) · Asher Schachter, M.D. (1) · Blai Coll, MD (1) · Brandon Triplett, MD (1) · C. William Wester, MD, MPH (1)
PMID 41805697, PMID 25660356, PMID 28756065, PMID 33107592, PMID 34778952, PMID 37916745, PMID 38018702, PMID 15660575, PMID 17167116, PMID 21965377, PMID 23320022, PMID 23333585, PMID 23804455, PMID 23889806, PMID 24622263, PMID 24722445, PMID 25607548, PMID 25899538, PMID 26153128, PMID 26235932, PMID 26896310, PMID 27110697, PMID 27320846, PMID 29104158, PMID 29386411, PMID 30957581, PMID 30992195, PMID 31023272, PMID 31027883, PMID 32559474, PMID 33121236, PMID 33130235, PMID 33184642, PMID 33587286, PMID 34169203, PMID 34383954, PMID 34805632, PMID 35869170, PMID 36645291, PMID 36821613, PMID 37254256, PMID 37528520, PMID 37716952, PMID 37916620, PMID 38017482, PMID 38299639, PMID 38770818, PMID 39382091, PMID 40193211, PMID 40478760
2016 (2), 2017 (2), 2018 (2), 2019 (2), R21AT004490 (2), 1KL2RR025015-01 (1), 2004 (1), 2009 (1), 2023 (1), I01CX000264 (1), K23HL127100 (1), P30CA016672 (1), P30DK017047 (1), R01HL111659 (1), R21AT002367 (1)